|

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

RECRUITINGPhase 4Sponsored by Taichung Veterans General Hospital
Actively Recruiting
PhasePhase 4
SponsorTaichung Veterans General Hospital
Started2019-08-19
Est. completion2027-12-31
Eligibility
Age20 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03933384

Summary

To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.

Eligibility

Age: 20 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Patients more than 20 years old
2. Chronic hepatitis B patients
3. Patients who were indicated for hepatitis B virus antiviral therapy

Exclusion Criteria:

1. Decompensated liver disease (Child-Pugh B \&C)
2. End stage renal disease (eGRF \< 15 ml/min/1.73m2)
3. Prior use of nucleot(s)ide analogues for chronic hepatitis B
4. Prior use of interferon for chronic hepatitis B within six months
5. Known history of human immunodeficiency virus or hepatitis C virus co-infection
6. Concurrent other uncontrolled malignancy
7. Women in pregnancy or lactation
8. Cannot conform to the study protocol of this study

Conditions3

Hepatitis BLiver DiseaseViral Hepatitis

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.